DK0759032T3 - Isolerede peptider, der er afledt fra MAGE-3, og som komplekserer med HLA-A2-molekyler, samt anvendelse heraf - Google Patents
Isolerede peptider, der er afledt fra MAGE-3, og som komplekserer med HLA-A2-molekyler, samt anvendelse herafInfo
- Publication number
- DK0759032T3 DK0759032T3 DK95914752T DK95914752T DK0759032T3 DK 0759032 T3 DK0759032 T3 DK 0759032T3 DK 95914752 T DK95914752 T DK 95914752T DK 95914752 T DK95914752 T DK 95914752T DK 0759032 T3 DK0759032 T3 DK 0759032T3
- Authority
- DK
- Denmark
- Prior art keywords
- mage
- hla
- complexing
- molecules
- peptides derived
- Prior art date
Links
- 102000025850 HLA-A2 Antigen Human genes 0.000 title abstract 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000000536 complexating effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/217,187 US5554506A (en) | 1994-03-24 | 1994-03-24 | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
PCT/US1995/003408 WO1995025739A1 (en) | 1994-03-24 | 1995-03-21 | Isolated, mage-3 derived peptides which complex with hla-a2 molecules and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0759032T3 true DK0759032T3 (da) | 1999-12-27 |
Family
ID=22810011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95914752T DK0759032T3 (da) | 1994-03-24 | 1995-03-21 | Isolerede peptider, der er afledt fra MAGE-3, og som komplekserer med HLA-A2-molekyler, samt anvendelse heraf |
Country Status (16)
Country | Link |
---|---|
US (3) | US5554506A (da) |
EP (1) | EP0759032B1 (da) |
JP (1) | JP3451356B2 (da) |
CN (1) | CN1142177C (da) |
AT (1) | ATE183195T1 (da) |
AU (1) | AU682956B2 (da) |
CA (1) | CA2186005A1 (da) |
DE (1) | DE69511399T2 (da) |
DK (1) | DK0759032T3 (da) |
ES (1) | ES2135051T3 (da) |
FI (1) | FI963781A0 (da) |
GR (1) | GR3031811T3 (da) |
NZ (1) | NZ283543A (da) |
TW (1) | TW496875B (da) |
WO (1) | WO1995025739A1 (da) |
ZA (1) | ZA952376B (da) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554506A (en) * | 1994-03-24 | 1996-09-10 | Ludwig Institute For Cancer Research | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
US5554724A (en) * | 1994-03-24 | 1996-09-10 | University Of Leiden | Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof |
US5686068A (en) * | 1994-03-24 | 1997-11-11 | Ludwig Institute For Cancer Research | Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof |
US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
US5587289A (en) * | 1995-03-14 | 1996-12-24 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof |
US5827073A (en) * | 1995-07-05 | 1998-10-27 | Ludwig Institute For Cancer Research | Photoreactive peptide derivatives |
US6087441A (en) | 1997-02-05 | 2000-07-11 | Ludwig Institute For Cancer Research | Structurally modified peptides that are resistant to peptidase degradation |
US6027924A (en) * | 1997-04-25 | 2000-02-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof |
US6680191B1 (en) | 1997-04-25 | 2004-01-20 | Ludwig Institute For Cancer | Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof |
US6025470A (en) | 1997-06-23 | 2000-02-15 | Ludwig Institute For Cancer Research | Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof |
CA2295321C (en) * | 1997-06-23 | 2008-01-29 | Ludwig Institute For Cancer Research | Isolated nona- and decapeptides which bind to hla molecules, and the use thereof |
ATE391726T1 (de) | 1999-10-22 | 2008-04-15 | Sanofi Pasteur Ltd | Modifiziertes gp100 und dessen verwendung |
US20020164654A1 (en) * | 2000-01-20 | 2002-11-07 | Rosalie Luiten | MAGE antigenic peptides which bind HLA-B35 and HLA-B44 |
WO2001085932A2 (en) | 2000-05-10 | 2001-11-15 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
WO2003085087A2 (en) | 2002-04-09 | 2003-10-16 | Aventis Pasteur, Limited | Modified cea nucleic acid and expression vectors |
EP2314712B1 (en) * | 2001-11-07 | 2014-01-08 | Mannkind Corporation | Expression vectors encoding epitopes of antigens and methods for their design |
US20070105779A1 (en) * | 2002-07-31 | 2007-05-10 | Danila Valmori | Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof |
JP4668919B2 (ja) * | 2003-10-08 | 2011-04-13 | サノフィ パストゥール インコーポレイテッド | 修飾cea/b7ベクター |
KR101304243B1 (ko) * | 2005-08-09 | 2013-09-05 | 온코세라피 사이언스 가부시키가이샤 | HLA-A2 양성 환자용 글리피칸-3(glypican-3)유래의 암 거절항원 펩티드 및 그를 포함하는 의약 |
JP5292550B2 (ja) * | 2007-03-23 | 2013-09-18 | 静岡県 | T細胞レセプターβ鎖遺伝子及びα鎖遺伝子 |
WO2010086294A2 (en) | 2009-01-28 | 2010-08-05 | Epimmune Inc. | Pan-dr binding polypeptides and uses thereof |
EP2480572B1 (en) | 2009-09-25 | 2019-01-30 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 and their use |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
NZ255683A (en) * | 1992-08-07 | 1996-08-27 | Cytel Corp | Immunogenic composition comprising a 9-10 aa residue peptide having a hla-a3.2, hla-a1, hla-a11 or hla-a24.1 binding motif |
US5405940A (en) * | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
US5462871A (en) * | 1992-08-31 | 1995-10-31 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode MAGE derived nonapeptides |
US5487974A (en) * | 1992-12-22 | 1996-01-30 | Ludwig Institute For Cancer-Research | Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells |
NZ263050A (en) * | 1993-03-05 | 1997-11-24 | Cytel Corp | Compositions of immunogenic peptides with hla-a2.1 binding motifs |
US5585461A (en) * | 1994-03-24 | 1996-12-17 | Ludwig Institute For Cancer Research | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
US5554506A (en) * | 1994-03-24 | 1996-09-10 | Ludwig Institute For Cancer Research | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
US5686068A (en) * | 1994-03-24 | 1997-11-11 | Ludwig Institute For Cancer Research | Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof |
-
1994
- 1994-03-24 US US08/217,187 patent/US5554506A/en not_active Expired - Lifetime
-
1995
- 1995-03-18 TW TW084102613A patent/TW496875B/zh active
- 1995-03-21 ES ES95914752T patent/ES2135051T3/es not_active Expired - Lifetime
- 1995-03-21 CN CNB951922602A patent/CN1142177C/zh not_active Expired - Lifetime
- 1995-03-21 WO PCT/US1995/003408 patent/WO1995025739A1/en active IP Right Grant
- 1995-03-21 DE DE69511399T patent/DE69511399T2/de not_active Expired - Lifetime
- 1995-03-21 EP EP95914752A patent/EP0759032B1/en not_active Expired - Lifetime
- 1995-03-21 DK DK95914752T patent/DK0759032T3/da active
- 1995-03-21 CA CA002186005A patent/CA2186005A1/en not_active Abandoned
- 1995-03-21 NZ NZ283543A patent/NZ283543A/en unknown
- 1995-03-21 AT AT95914752T patent/ATE183195T1/de active
- 1995-03-21 JP JP52473895A patent/JP3451356B2/ja not_active Expired - Lifetime
- 1995-03-21 AU AU21870/95A patent/AU682956B2/en not_active Expired
- 1995-03-23 ZA ZA952376A patent/ZA952376B/xx unknown
-
1996
- 1996-06-21 US US08/668,560 patent/US6019987A/en not_active Expired - Lifetime
- 1996-09-23 FI FI963781A patent/FI963781A0/fi unknown
-
1999
- 1999-07-07 US US09/348,797 patent/US6353089B1/en not_active Expired - Lifetime
- 1999-11-10 GR GR990402904T patent/GR3031811T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0759032B1 (en) | 1999-08-11 |
JP3451356B2 (ja) | 2003-09-29 |
CA2186005A1 (en) | 1995-09-28 |
JPH10500667A (ja) | 1998-01-20 |
FI963781A (fi) | 1996-09-23 |
FI963781A0 (fi) | 1996-09-23 |
WO1995025739A1 (en) | 1995-09-28 |
EP0759032A1 (en) | 1997-02-26 |
US5554506A (en) | 1996-09-10 |
GR3031811T3 (en) | 2000-02-29 |
NZ283543A (en) | 1998-04-27 |
ES2135051T3 (es) | 1999-10-16 |
DE69511399T2 (de) | 2000-05-11 |
ZA952376B (en) | 1995-12-14 |
TW496875B (en) | 2002-08-01 |
ATE183195T1 (de) | 1999-08-15 |
US6019987A (en) | 2000-02-01 |
AU2187095A (en) | 1995-10-09 |
EP0759032A4 (en) | 1997-04-09 |
AU682956B2 (en) | 1997-10-23 |
CN1142177C (zh) | 2004-03-17 |
CN1151167A (zh) | 1997-06-04 |
US6353089B1 (en) | 2002-03-05 |
DE69511399D1 (de) | 1999-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0759032T3 (da) | Isolerede peptider, der er afledt fra MAGE-3, og som komplekserer med HLA-A2-molekyler, samt anvendelse heraf | |
CA2186004A1 (en) | Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules | |
DK0810870T3 (da) | Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf | |
ES2080717T3 (es) | Hibridomas productores de anticuerpos monoclonales para nuevos epitopos de mucina. | |
FI956019A (fi) | Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA-C-klooni-10:n kanssa, ja niiden käyttö | |
HUT38300A (en) | Process for producing growth-controlling composition attached to the platelets | |
NO20021992L (no) | Anti-prostatastamcelleantigen(PSCA)-antistoffpreparat og fremgangsmåter for anvendelse | |
EP0845032A4 (en) | ISOLATED NUCLEIC ACID MOLECULES, PEPTIDES FORMING COMPLEXES WITH THE MOLECULE OF THE MAJOR HLA-A2 HISTOCOMPATIBILITY COMPLEX (MHC) AND THEIR APPLICATIONS | |
ZA975851B (en) | Hepatocyte grown factor receptor agonists and uses thereof | |
NZ237688A (en) | Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment | |
IL79260A (en) | Process and composition for activation of immune response cells to be used in the treatment of cancer,non-malignant tumors,infections,and immune deficiencies | |
NO965087L (no) | Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav | |
NO963917L (no) | Isolerte, MAGE-3-avledete peptider som komplekserer med HLA-A2-molekyler, samt anvendelser derav | |
Townsend et al. | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof | |
RU2000132677A (ru) | Моноклональное антитело ико25, специфичное к антигену мис1, противоопухолевое средство |